Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
AIMS/HYPOTHESIS: The evidence on the association between pioglitazone use and bladder cancer is contradictory, with many studies subject to allocation bias. The aim of our study was to examine the effect of exposure to pioglitazone on bladder cancer risk internationally across several cohorts. The potential for allocation bias was minimised by focusing on the cumulative effect of pioglitazone as the primary endpoint using a time-dependent approach. METHODS: Prescription, cancer and mortality data from people with type 2 diabetes were obtained from six populations across the world (British Columbia, Finland, Manchester, Rotterdam, Scotland and the UK Clinical Practice Research Datalink). A discrete time failure analysis using Poisson regression was applied separately to data from each centre to model the effect of cumulative drug exposure on bladder cancer incidence, with time-dependent adjustment for ever use of pioglitazone. These were then pooled using fixed and random effects meta-regression. RESULTS: Data were collated on 1.01 million persons over 5.9 million person-years. There were 3,248 cases of incident bladder cancer, with 117 exposed cases and a median follow-up duration of 4.0 to 7.4 years. Overall, there was no evidence for any association between cumulative exposure to pioglitazone and bladder cancer in men (rate ratio [RR] per 100 days of cumulative exposure, 1.01; 95% CI 0.97, 1.06) or women (RR 1.04; 95% CI 0.97, 1.11) after adjustment for age, calendar year, diabetes duration, smoking and any ever use of pioglitazone. No association was observed between rosiglitazone and bladder cancer in men (RR 1.01; 95% CI 0.98, 1.03) or women (RR 1.00; 95% CI 0.94, 1.07). CONCLUSIONS/INTERPRETATION: The cumulative use of pioglitazone or rosiglitazone was not associated with the incidence of bladder cancer in this large, pooled multipopulation analysis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, more recent studies48,49 showed no significant association for any dose or duration of therapy.49”
From Pioglitazone after Ischemic Stroke or Transient Ischemic Attack (2016) · cites this paper as [48]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,293
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone
Lewis, J. D., Ferrara, A., Peng, T., Hedderson, M., Bilker, W. B., Quesenberry, C. P., Vaughn, D. J., Nessel, L., Selby, J., & Strom, B. L. (2011) · Diabetes Care · doi:10.2337/dc10-1068 · Cited by 625
Metformin and the Risk of Cancer
Suissa, S., & Azoulay, L. (2012) · Diabetes Care · doi:10.2337/dc12-0788 · Cited by 531
Diabetes mellitus and risk of bladder cancer: a meta-analysis
Larsson, S. C., Orsini, N., Brismar, K., & Wolk, A. (2006) · Diabetologia · doi:10.1007/s00125-006-0468-0 · Cited by 304
Neumann, A., Weill, A., Ricordeau, P., Fagot, J. P., Alla, F., & Allemand, H. (2012) · Diabetologia · doi:10.1007/s00125-012-2538-9 · Cited by 284 · cited 7×
“Furthermore, the study by Neumann et al used never exposed participants as the reference group and did not adjust for smoking.”
BackgroundResultInfluentialAzoulay, L., Yin, H., Filion, K. B., Assayag, J., Majdan, A., Pollak, M. N., & Suissa, S. (2012) · BMJ · doi:10.1136/bmj.e3645 · Cited by 270
Piccinni, C., Motola, D., Marchesini, G., & Poluzzi, E. (2011) · Diabetes Care · doi:10.2337/dc10-2412 · Cited by 239 · cited 1×
“Wei et al [23] UK 2012 66 869 Piccinni et al [19] USA 2011 31 93”
On the Treatment of Grouped Observations in Life Studies
Jr., W. A. T. (1977) · Biometrics · doi:10.2307/2529360 · Cited by 227
Cited by
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
“Bladder cancer has been a concern, with population-based studies reporting either positive or negative associations.((169-171)) However, Lewis et al.”
DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.19 · Cited by 2,611
Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends
Antoni, S., Ferlay, J., Soerjomataram, I., Znaor, A., Jemal, A., & Bray, F. (2017) · European Urology · doi:10.1016/j.eururo.2016.06.010 · Cited by 2,514
Nonalcoholic Fatty Liver Disease: A Systematic Review
Rinella, M. E. (2015) · JAMA · doi:10.1001/jama.2015.5370 · Cited by 2,267
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
Kernan, W. N., Viscoli, C. M., Furie, K. L., Young, L. H., Inzucchi, S. E., Gorman, M., Guarino, P. D., Lovejoy, A. M., Peduzzi, P. N., Conwit, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506930 · Cited by 1,124
Cusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1774 · Cited by 1,024
PPARs in Obesity-Induced T2DM, Dyslipidaemia and NAFLD
Gross, B., Pawlak, M., Lefebvre, P., & Staels, B. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.135 · Cited by 778
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
JCS 2018 Guideline on Diagnosis and Treatment of Acute Coronary Syndrome
Kimura, K., Kimura, T., Ishihara, M., Nakagawa, Y., Nakao, K., Miyauchi, K., Sakamoto, T., Tsujita, K., Hagiwara, N., Miyazaki, S., et al. (2019) · Circulation Journal · doi:10.1253/circj.cj-19-0133 · Cited by 565
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Diabetes: Advances in Diagnosis and Treatment
Nathan, D. M. (2015) · JAMA · doi:10.1001/jama.2015.9536 · Cited by 384
The Rotterdam Study: 2016 objectives and design update
Hofman, A., Brusselle, G. G. O., Murad, S. D., van Duijn, C. M., Franco, O. H., Goedegebure, A., Ikram, M. A., Klaver, C. C. W., Nijsten, T. E. C., Peeters, R. P., et al. (2015) · European Journal of Epidemiology · doi:10.1007/s10654-015-0082-x · Cited by 382
Self-citationPoly Cystic Ovarian Syndrome: An Updated Overview
El Hayek, S., Bitar, L., Hamdar, L. H., Mirza, F. G., & Daoud, G. (2016) · Frontiers in Physiology · doi:10.3389/fphys.2016.00124 · Cited by 323
Current efforts and trends in the treatment of NASH
Ratziu, V., Goodman, Z., & Sanyal, A. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.041 · Cited by 262
Epidemiology of urothelial carcinoma
Miyazaki, J., & Nishiyama, H. (2017) · International Journal of Urology · doi:10.1111/iju.13376 · Cited by 253
Pharmacologic Glycemic Management of Type 2 Diabetes in Adults
Lipscombe, L., Booth, G., Butalia, S., Dasgupta, K., Eurich, D. T., Goldenberg, R., Khan, N., MacCallum, L., Shah, B. R., & Simpson, S. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.034 · Cited by 246
Pioglitazone use and risk of bladder cancer: Population based cohort study
Tuccori, M., Filion, K. B., Yin, H., Yu, O. H., Platt, R. W., & Azoulay, L. (2016) · BMJ · doi:10.1136/bmj.i1541 · Cited by 237
PPARs as Nuclear Receptors for Nutrient and Energy Metabolism
Hong, F., Pan, S., Guo, Y., Xu, P., & Zhai, Y. (2019) · Molecules · doi:10.3390/molecules24142545 · Cited by 233
“Hence, in the United States, it has been withdrawn from use (as pioglitazone has been) [144].”
BackgroundPioglitazone: the forgotten, cost-effective cardioprotective drug for type 2 diabetes
DeFronzo, R. A., Inzucchi, S., Abdul-Ghani, M., & Nissen, S. E. (2019) · Diabetes and Vascular Disease Research · doi:10.1177/1479164118825376 · Cited by 223
Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing?
Klil-Drori, A. J., Azoulay, L., & Pollak, M. N. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.120 · Cited by 210
Ghosh, A., Tyson, T., George, S., Hildebrandt, E. N., Steiner, J. A., Madaj, Z., Schulz, E., Machiela, E., McDonald, W. G., Escobar Galvis, M. L., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aag2210 · Cited by 189
Pioglitazone and bladder cancer risk: a systematic review and meta‐analysis
Tang, H., Shi, W., Fu, S., Wang, T., Zhai, S., Song, Y., & Han, J. (2018) · Cancer Medicine · doi:10.1002/cam4.1354 · Cited by 154
Khetan, A. K., & Rajagopalan, S. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.12.030 · Cited by 147
Management of diabetes mellitus in patients with chronic kidney disease
Hahr, A. J., & Molitch, M. E. (2015) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-015-0001-9 · Cited by 142
de Jong, M., van der Worp, H. B., van der Graaf, Y., Visseren, F. L. J., & Westerink, J. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0617-4 · Cited by 132
Hong, F., Xu, P., & Zhai, Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082189 · Cited by 139
“Thus, the FDA issued an alert about a potential relation between the incidence of bladder cancer and the prescription of pioglitazone [35].”
BackgroundPioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study
Rousselot, P. H., Prost, S., Guilhot, J., Roy, L., Étienne, G., Legros, L., Charbonnier, A., Coiteux, V., Cony‐Makhoul, P., Huguet, F., et al. (2016) · Cancer · doi:10.1002/cncr.30490 · Cited by 106
Practice patterns in NAFLD and NASH: real life differs from published guidelines
Rinella, M. E., Lominadze, Z., Loomba, R., Charlton, M., Neuschwander-Tetri, B. A., Caldwell, S. H., Kowdley, K., & Harrison, S. A. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x15611581 · Cited by 95
Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis
Filipova, E., Uzunova, K., Kalinov, K., & Vekov, T. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0273-4 · Cited by 87
Ban, L., Sprigg, N., Sultan, A. A., Nelson‐Piercy, C., Bath, P. M., Ludvigsson, J. F., Stephansson, O., & Tata, L. J. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.004601 · Cited by 94
Novel Diabetes Drugs and the Cardiovascular Specialist
Sattar, N. A., Petrie, M. C., Zinman, B., & Januzzi, J. L. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.04.014 · Cited by 93
Johnston, R., Uthman, O. A., Cummins, E., Clar, C., Royle, P., Colquitt, J. L., Tan, B. K., Clegg, A. J., Shantikumar, S., Court, R. A., et al. (2017) · Health Technology Assessment · doi:10.3310/hta21020 · Cited by 92
Xu, Y., Wu, Y., & Huang, Q. (2017) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-017-4480-z · Cited by 78
Unraveling the Effects of PPARβ/δ on Insulin Resistance and Cardiovascular Disease
Vázquez-Carrera, M. (2016) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.02.008 · Cited by 71
Erdmann, E., Harding, S., Lam, H., & Perez, A. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12608 · Cited by 80
Dawed, A. Y., Donnelly, L. A., Tavendale, R., Carr, F., Leese, G., Palmer, C. N. A., Pearson, E. R., & Zhou, K. (2016) · Diabetes Care · doi:10.2337/dc15-2464 · Cited by 76
The current role of thiazolidinediones in diabetes management
Rizos, C. V., Kei, A. A., & Elisaf, M. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1737-4 · Cited by 75
Korhonen, P. A., Heintjes, E. M., Williams, R., Hoti, F. J., Christopher, S., Majak, M., Kool-Houweling, L., Strongman, H., Linder, M., Dolin, P., et al. (2016) · BMJ · doi:10.1136/bmj.i3903 · Cited by 71
Merlin, J., Evans, B. A., Dehvari, N., Sato, M., Bengtsson, T., & Hutchinson, D. S. (2015) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201500251 · Cited by 63
Zhang, Y., Kong, W., & Jiang, J. (2017) · Science China Life Sciences · doi:10.1007/s11427-017-9047-4 · Cited by 61
Arrese, M., Barrera, F., Triantafilo, N., & Arab, J. P. (2019) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2019.1649981 · Cited by 54
Tanaka, R., Yamashiro, K., Okuma, Y., Shimura, H., Nakamura, S., Ueno, Y., Tanaka, Y., Miyamoto, N., Tomizawa, Y., Nakahara, T., et al. (2015) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.30007 · Cited by 56
DeFronzo, R. A., CHILTON, R. J., Norton, L., Clarke, G., Ryder, R. E. J., & Abdul‐Ghani, M. A. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12652 · Cited by 55
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
Viscoli, C. M., Kernan, W. N., & Young, L. H. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1605904 · Cited by 50
Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agents
Pearson, E. R., Dawed, A. Y., & Zhou, K. (2016) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s84854 · Cited by 49
Beard, E., Shahab, L., Cummings, D. M., Michie, S., & West, R. (2016) · CNS Drugs · doi:10.1007/s40263-016-0362-3 · Cited by 48
Non-alcoholic Fatty Liver Disease and Diabetes Mellitus
Khneizer, G. W., Rizvi, S., & Gawrieh, S. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2020_532 · Cited by 44
Caparrotta, T. M., Dear, J. W., Colhoun, H. M., & Webb, D. J. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14024 · Cited by 43
Self-citationVeleba, J., Kopecký, J., Janovská, P., Kuda, O., Horakova, O., Malínská, H., Kazdová, L., Oliyarnyk, O., Škop, V., Trnovská, J., et al. (2015) · Nutrition & Metabolism · doi:10.1186/s12986-015-0047-9 · Cited by 43
Critical analysis of carcinogenicity study outcomes. Relationship with pharmacological properties
van der Laan, J. W., Kasper, P., Lima, B. S., Jones, D. R., & Pasanen, M. (2016) · Critical Reviews in Toxicology · doi:10.3109/10408444.2016.1163664 · Cited by 42
Traussnigg, S., Kienbacher, C., Halilbasic, E., Rechling, C., Kazemi-Shirazi, L., Hofer, H., Munda, P., & Trauner, M. (2015) · Digestive Diseases · doi:10.1159/000375353 · Cited by 40
Santos, J. C., Bernardes, A., Giampietro, L., Ammazzalorso, A., Filippis, B. D., Amoroso, R., & Polikarpov, I. (2015) · Journal of Structural Biology · doi:10.1016/j.jsb.2015.07.006 · Cited by 39
Yan, H., Xie, H., Ying, Y., Li, J., Wang, X., Xu, X., & Zheng, X. (2018) · Cancer Management and Research · doi:10.2147/cmar.s164840 · Cited by 39
Ripamonti, E., Azoulay, L., Abrahamowicz, M., Platt, R. W., & Suissa, S. (2018) · Diabetic Medicine · doi:10.1111/dme.13854 · Cited by 39
Mehtälä, J., Khanfir, H., Bennett, D., Ye, Y., Korhonen, P. A., & Hoti, F. J. (2018) · Diabetology International · doi:10.1007/s13340-018-0360-4 · Cited by 37
Rosiglitazone Use and the Risk of Bladder Cancer in Patients With Type 2 Diabetes
Han, E., Jang, S., Kim, G., Lee, Y., Choe, E. Y., Nam, C. M., & Kang, E. S. (2016) · Medicine · doi:10.1097/md.0000000000002786 · Cited by 37
Davidson, M. B., & Pan, D. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.11.002 · Cited by 38
Sund, R., Gissler, M., Hakulinen, T. R., & Rosén, M. (2013) · Springer eBooks · doi:10.1007/978-0-387-09834-0_5 · Cited by 36
Self-citationBiondo, L. A., Teixeira, A. A. S., Ferreira, K. C. D. O. S., & Neto, J. C. R. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200122124116 · Cited by 35
Thiazolidinedione as a Promising Medicinal Scaffold for the Treatment of Type 2 Diabetes
Singh, G., Kumar, R., Desna, D. S., Chaudhary, M., Kaur, C., & Khurana, N. (2023) · Current Diabetes Reviews · doi:10.2174/0115733998254798231005095627 · Cited by 36
Grivas, P. D., Melas, M., & Papavassiliou, A. G. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.08.006 · Cited by 33
FinDM database on diabetes in Finland
Arffman, M., Ilanne‐Parikka, P., Keskimäki, I., Kurkela, O., Lindström, J., Sund, R., & Winell, K. (2020) · STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) · Cited by 31
Self-citationSuzuki, S., Mori, Y., Nagano, A., Naiki‐Ito, A., Kato, H., Nagayasu, Y., Kobayashi, M., Kuno, T., & Takahashi, S. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122071 · Cited by 31
Treatment options for nonalcoholic steatohepatitis - a safety evaluation
Issa, D., Wattacheril, J. J., & Sanyal, A. J. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1343299 · Cited by 30
Current Treatment of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
Hung, C. K., & Bodenheimer, H. C. (2017) · Clinics in Liver Disease · doi:10.1016/j.cld.2017.08.012 · Cited by 30
Diabetes Mellitus Type 2: A Driving Force for Urological Complications
Sayyid, R. K., & Fleshner, N. E. (2016) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2016.02.006 · Cited by 29
Drug–subphenotype interactions for cancer in type 2 diabetes mellitus
Yang, X., Lee, H. M., & Chan, J. C. N. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.37 · Cited by 28
Essentials of bladder cancer worldwide: incidence, mortality rate and risk factors
Gandomani, H. S., Tarazoj, A. A., Siri, F. H., Rozveh, A. K., Hosseini, S., Borujeni, N. N., Mohammadian-Hafshejani, A., & Salehiniya, H. (2017) · Biomedical Research and Therapy · doi:10.15419/bmrat.v4i9.371 · Cited by 27
Pioglitazone for advanced fibrosis in nonalcoholic steatohepatitis: new evidence, new challenges
Musso, G., Cassader, M., Paschetta, E., & Gambino, R. (2017) · Hepatology · doi:10.1002/hep.28960 · Cited by 26
“Nevertheless, the benefits of pioglitazone treatment should be weighed against the side effects of this drug, including weight gain, bone loss, edema, and fluid retention, while recent evidence challenges the increased risk for bladder cancer.((6)) Therefore, a key issue in current clinical practice will be to develop…”
BackgroundMelatonin May Increase Anticancer Potential of Pleiotropic Drugs
Bojková, B., Kubatka, P., Qaradakhi, T., Zulli, A., & Kajo, K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123910 · Cited by 25
Liu, J., Zhang, B., Zhang, G., & Shang, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1345838 · Cited by 24
Diabetes Pharmacotherapies and Bladder Cancer: A Medicare Epidemiologic Study
MacKenzie, T. A., Zaha, R. L., Smith, J., Karagas, M. R., & Morden, N. E. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0152-4 · Cited by 24
Alogliptin benzoate for management of type 2 diabetes
Saisho, Y. (2015) · Vascular Health and Risk Management · doi:10.2147/vhrm.s68564 · Cited by 24
Pioglitazone and the risk of bladder cancer: An Indian retrospective cohort study
Gupta, S., Gupta, K., Ravi, R., Mehta, V., Banerjee, S., Joshi, S., & Saboo, B. (2015) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.163187 · Cited by 23
Using Large Diabetes Databases for Research
Wild, S. H., Fischbacher, C., & McKnight, J. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816645120 · Cited by 23
Self-citationBouchi, R., Kondo, T., Ohta, Y., Goto, A., Tanaka, D., Satoh, H., Yabe, D., Nishimura, R., Harada, N., Kamiya, H., et al. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14202 · Cited by 22
Bouchi, R., Kondo, T., Ohta, Y., Goto, A., Tanaka, D., Satoh, H., Yabe, D., Nishimura, R., Harada, N., Kamiya, H., et al. (2024) · Diabetology International · doi:10.1007/s13340-024-00723-8 · Cited by 21
Prato, S. D., & CHILTON, R. J. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13169 · Cited by 22
AlQumaizi, K. I., Anwer, R., Ahmad, N., Alosaimi, S. M., & Fatma, T. (2018) · Journal of Molecular Recognition · doi:10.1002/jmr.2735 · Cited by 21
Pioglitazone Use and Risk of Bladder Cancer: an In Vitro Study
Yang, S., Wang, J., Chen, M., Xu, L., Li, N., Luo, Y., Bu, L., Zhang, M., Li, H., & Su, B. (2018) · International Journal of Medical Sciences · doi:10.7150/ijms.22408 · Cited by 20
Kim, B., Kwon, H., Kim, S. K., Noh, J.-H., Park, C., Park, H.-K., Song, K.-H., Won, J. C., Yu, J. M., Lee, M. Y., et al. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0264 · Cited by 20
El‐Gowilly, S. M., Helmy, M. M., & El‐Gowelli, H. M. (2015) · Vascular Pharmacology · doi:10.1016/j.vph.2015.07.002 · Cited by 20
Selecting the right drug treatment for adults with type 2 diabetes
Montori, V. M. (2016) · BMJ · doi:10.1136/bmj.i1663 · Cited by 20
An overview of alogliptin + pioglitazone for the treatment of type 2 diabetes
Tomlinson, B., Chan, P., & Lam, C. W. K. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1985465 · Cited by 19
Skoczyńska, A., Ołdakowska, M., Dobosz, A., Adamiec, R., Gritskevich, S., Jonkisz, A., Lebioda, A., Adamiec-Mroczek, J., Małodobra-Mazur, M., & Dobosz, T. (2024) · Biomolecules · doi:10.3390/biom14070786 · Cited by 18
Dedov, I. I., Shestakova, M. V., As, A., Анциферов, М. Б., Galstyan, G. R., Mayorov, A. Y., Mkrtumyan, A. M., Petunina, N. A., & Sukhareva, O. Y. (2015) · Diabetes Mellitus · doi:10.14341/dm201515-23 · Cited by 18
Pioglitazone (Actos) and bladder cancer: Legal system triumphs over the evidence
Davidson, M. B. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.04.004 · Cited by 18
Qu, H., Zheng, Y., Wang, Y., Zhang, R., Ruan, X. Z., Yang, G., Liu, Z., & Zheng, H. (2017) · Scientific Reports · doi:10.1038/s41598-017-16074-1 · Cited by 16
How to Reduce Cardiovascular Risk in Nonalcoholic Fatty Liver Disease
Ismaiel, A., & Dumitrascu, D. L. (2020) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001174 · Cited by 16
From Current Therapeutics to Multitarget Ligands: A Review of Diabetes Pharmacological Treatments
Cabré, F., Centelles, J. J., & Cascante, M. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17091125 · Cited by 16
Prabhakaran, P., Shanmugarajan, D., Kumar, T. D. A., & Kumar, B. R. P. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1841677 · Cited by 15
Bannister, M., & Berlanga, J. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0188-5 · Cited by 14
Modelling cumulative exposure for inference about drug effects in observational studies
Farran, B., McGurnaghan, S. J., Looker, H. C., Livingstone, S. J., Lahnsteiner, E., Colhoun, H. M., & McKeigue, P. (2017) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4327 · Cited by 14
Self-citationBushi, G., Gaidhane, S., Ballal, S., Kumar, S., Bhat, M., Sharma, S., Kumar, M. R., Sinha, A., Khatib, M. N., Rai, N., et al. (2025) · Health Science Reports · doi:10.1002/hsr2.70490 · Cited by 13
“TZDs, such as pioglitazone, have also been implicated in cancer risk, with studies demonstrating a dose ‐ dependent relationship between cumulative exposure and bladder cancer incidence [29, 30].”
Pioglitazone, Bladder Cancer, and the Presumption of Innocence
Papaetis, G. S. (2022) · Current Drug Safety · doi:10.2174/1574886317666220304124756 · Cited by 13
Influence of modern antidiabetic therapy on body weight in patients with type 2 diabetes mellitus
Салухов, В. В., Ilyinskaya, Т. A., & Minakov, A. A. (2022) · Endocrinology News Opinions Training · doi:10.33029/2304-9529-2022-11-1-39-52 · Cited by 14
All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine
Strandberg, A. Y., Hoti, F. J., Strandberg, T. E., Christopher, S., Haukka, J. K., & Korhonen, P. A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151910 · Cited by 13
Ishii, H. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13799 · Cited by 12
Laying the foundations for disease-modifying therapies in PD
Brundin, P., & Wyse, R. K. H. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.150 · Cited by 12
Metadata
- Authors
- on behalf of the Scottish Diabetes Research Network Epidemiology Group and the Diabetes and Cancer Research Consortium, Levin, D., Bell, S., Sund, R., Hartikainen, S. A., Tuomilehto, J., Pukkala, E., Keskimäki, I., Badrick, E., Renehan, A. G., Buchan, I. E., Bowker, S. L., Minhas-Sandhu, J. K., Zafari, Z., Marra, C., Johnson, J. A., Stricker, B. H., Uitterlinden, A. G., Hofman, A., Ruiter, R., de Keyser, C. E., MacDonald, T. M., Wild, S. H., McKeigue, P. M., & Colhoun, H. M.
- Affiliations
- University of Dundee (GB)
- Ninewells Hospital (GB)
- University of Helsinki (FI)
- University of Eastern Finland (FI)
- Universität für Weiterbildung Krems (AT)
- Finnish Cancer Registry (FI)
- Finnish Institute for Health and Welfare (FI)
- University of Manchester (GB)
- University of Alberta (CA)
- University of British Columbia (CA)
- Erasmus MC (NL)
- Groene Hart Ziekenhuis (NL)
- University of Edinburgh (GB)
- Corresponding author
- Bell, Samira
- ORCID
- Venue
- Diabetologia
- Published
- 2014-12-07
- Volume
- 58
- Issue
- 3
- Pages
- 493-504
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2069723602
- Cited by
- 158
- References
- 32
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 9 · 2023: 4 · 2022: 7 · 2021: 5 · 2020: 6 · 2019: 9 · 2018: 14 · 2017: 25 · 2016: 37 · 2015: 33 · 2014: 1
- FWCI
- 13.11
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Discovery Research Portal (University of Dundee) (submittedVersion)
- STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) (submittedVersion)
- WOS
- Funders
- University of Dundee
- European Foundation for the Study of Diabetes
- Medical Research Council (MR/K006665/1, MR/M501633/1, MC_PC_13042, MR/K007017/1)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- pioglitazone, rosiglitazone, bladder cancer, type 2 diabetes, thiazolidinediones, drug-induced cancer risk, cumulative drug exposure, allocation bias, cancer incidence, pooled analysis
- MeSH terms
- Rosiglitazone, Pioglitazone, Aged, Urinary Bladder Neoplasms, British Columbia, Diabetes Mellitus, Type 2, Female, Finland, Humans, Hypoglycemic Agents, Male, Middle Aged, Scotland, Incidence, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.